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Abstract
Rotavirus (RV) P[11] is an unique genotype that infects neonates. The mechanism of such age-specific host restriction
remains unknown. In this study, we explored host mucosal glycans as a potential age-specific factor for attachment of P[11]
RVs. Using in vitro binding assays, we demonstrated that VP8* of a P[11] RV (N155) could bind saliva of infants (60.3%,
N = 151) but not of adults (0%, N = 48), with a significantly negative correlation between binding of VP8* and ages of infants
(P,0.01). Recognition to the infant saliva did not correlate with the ABO, secretor and Lewis histo-blood group antigens
(HBGAs) but with the binding of the lectin Lycopersicon esculentum (LEA) that is known to recognize the oligomers of N-
acetyllactosamine (LacNAc), a precursor of human HBGAs. Direct evidence of LacNAc involvement in P[11] binding was
obtained from specific binding of VP8* with homopolymers of LacNAc in variable lengths through a glycan array analysis of
611 glycans. These results were confirmed by strong binding of VP8* to the Lec2 cell line that expresses LacNAc oligomers
but not to the Lec8 cell line lacking the LacNAc. In addition, N155 VP8* and authentic P[11] RVs (human 116E and bovine
B223) hemagglutinated human red blood cells that are known to express poly-LacNAc. The potential role of poly-LacNAc in
host attachment and infection of RVs has been obtained by abrogation of 116E replication by the PAA-conjugated poly-
LacNAc, human milk, and LEA positive infant saliva. Overall, our results suggested that the poly-LacNAc could serve as an
age-specific receptor for P[11] RVs and well explained the epidemiology that P[11] RVs mainly infect neonates and young
children.
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Introduction
Attachment to a host receptor is the essential first step for many
bacterial and viral pathogens to initiate an infection [1]. As
carbohydrates, the histo-blood group antigens (HBGAs), including
those in the ABO, secretor and Lewis families, distribute
abundantly on the surfaces of red blood cells and mucosal
epithelia, serving as receptors of some pathogens [2]. These
HBGAs are also present in soluble form in biologic fluids such as
saliva and milk [3]. HBGAs are synthesized by glycosyltransferases
from a series of precursor structures by stepwise addition of
monosaccharide units [4]. Understanding human HBGAs as
receptors of pathogens has been significantly advanced over the
past decade through study of human noroviruses, a major cause of
acute gastroenteritis. Human noroviruses are diverse in recogniz-
ing variable HBGA [5–8]. Direct evidence regarding HBGAs in
host susceptibility/resistance to norovirus infection has been
obtained by human volunteer challenge studies and outbreak
investigations [9,10].
Recently, human rotaviruses (RVs), another major cause of
severe diarrhea in children, have also been found to recognize the
human HBGAs as potential receptors or attachment factors
similar to that of human noroviruses. The RV-HBGA interaction
was first demonstrated by binding of recombinant spike VP8*
proteins of major human RVs to specific HBGAs [11]. Strains in
the P[4] and P[8] genotypes share the common antigens of Lewis
b (Leb) and H type 1, while strains of the P[6] genotype bind the H
type 1 antigen only. The bindings were demonstrated using
human saliva, milk, and synthetic HBGA oligosaccharides and the
binding was also observed when authentic viruses from a cell
culture derived P[8] (Wa) RV were tested.
Following the first study, a phylogenetic analysis of RVs based
on the VP8* sequences was performed. These studies demon-
strated that RVs can be grouped into five P genogroups (P[I]–
P[V]) with clear segregation between human and animal RVs in
which P[I] and P[V] mainly infect animals, P[II] infects humans,
while P[III] and P[IV] infect both animals and humans [12]. The
three major P genotypes of human RVs (P[4], [6] and [8])
recognizing the H-related antigens (Leb and H type 1) described in
the first study were all clustered in P[II], suggesting HBGAs as an
important determinant of host ranges of RVs. Another study on
three genotypes (P[9], [14] and [25]) in P [III] resulted in
discovery of a new HBGA binding pattern of RVs; all the three
genotypes recognized the type A antigen distinct from the P[II]
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RVs [12]. In addition, the VP8* of the three P[III] RVs bound the
A antigens of the porcine and bovine mucins, suggesting the A
antigen as a shared ligand for cross-species transmission of RVs.
Direct evidence of the RV-HBGA interaction came from an x-ray
crystallography of VP8* of a P[14] RV in complex with the A-
oligosaccharides showing the HBGA-binding site of RV. Further
study demonstrated a specific inhibition of RV infection in cell
culture by an anti-A monoclonal antibody, suggesting the A
antigen as a receptor of the P[14] RV [13].
The recognition of carbohydrate receptors by RVs can be
traced back to the finding of the sialic acid as a receptor for some
animal RVs [14,15], suggesting that the recognition of a
carbohydrate receptor could be a common feature of RVs. It
also was found that the same receptor binding interfaces of the A-
binding human RVs (P[14]) are shared with the sialic acid-
depended animal RVs in the VP8* proteins [13], suggesting a
convergent structure for carbohydrate interactions in evolution of
RVs. RVs are highly adaptive viruses that infect humans and
different animals. While animal RVs may recognize animal
specific carbohydrates, human RVs recognize human HBGAs.
The adaptive nature of RVs and the polymorphic human HBGAs
prompted us to look for other potential binding patterns of RVs.
In this study we demonstrated the carbohydrate binding pattern
of another genotype, P[11] of human RVs. P[11] is the sole
genotype in P[IV] genogroup that mainly infects cattle and
humans with a preference of neonates. The genetic segregation of
P[11] (P[IV]) from the other RV genotypes and genogroups and
its unique host range for neonates prompted us to search for a
potential age specific ligand for P[11] RVs. By in vitro binding
assays of RV surface spike protein VP8* with large numbers of
saliva samples from neonates/infants and adults as well as a large
carbohydrate array, we have demonstrated that P[11] RVs
specifically recognize a precursor of human HBGAs, the poly-
LacNAc, that are available in mucosa of neonates and infants as
potential receptors for P[11] RVs. The observed binding
specificity and its biologic relevance was further proved by cell
culture based binding and infection assays.
Materials and Methods
Protein expression and purification
The VP8* sequences (amino acids 46-231) of a human RV
P[11] strain N155 (GenBank accession: EU200796) were synthe-
sized by GenScrip (GenScript USA Inc., Piscataway, NJ), and then
sub-cloned into the expression vector PGEX-4T-1(GE Healthcare
Life Sciences, Piscataway, NJ) between the BamH I and Sal I sites.
After confirmation of the inserts through DNA sequencing, the
GST-VP8* fusion protein was expressed in E. coli BL21 with
induction of IPTG (0.4 mM) at room temperature (,22uC)
overnight. The GST-VP8* fusion protein was purified using
Glutathione Sepharose 4 Fast Flow (GE Healthcare Life Sciences,
Piscataway, NJ) according to the manufacturer’s protocol. Briefly,
bacterial lysates were mixed with the sepharose beads for 2 h at
room temperature to allow the GST fused VP8* proteins binding
to the beads. After washing the beads with PBS for 4–6 times, the
GST fusion VP8* proteins were eluted by glutathione elution
buffer (10 mM reduced glutathione, 50 mM Tris-Cl, PH 8.0).
Saliva collection
Written informed consent was obtained from the parents of the
infants. Samples were collected from infants born in Cincinnati,
Ohio under IRB-approved protocols (Cincinnati Children’s
Hospital Medical Center Institutional Review Board study#
2008-0463 and 2008-1131). Whole saliva was collected from
preterm infants ,33 weeks of age at day 8 of life who were
enrolled in two hospital neonatal intensive care units (Novel
Biomarkers Cohort). Collection was conducted early in the
morning by trained clinical nurses. Two sterile cotton swabs were
placed between the check and the gum and held in place until
saturated. A similar procedure was used for collection of whole
saliva from healthy, term infants enrolled in a longitudinal study of
breastfeeding and infant health (GEHM Study, HD13021), at
standardized postnatal intervals (weeks of life 2, 4, 13, 26, and 52).
For the latter study, samples were collected by two trained
research staff between 9 am and noon. Immediately after
collection, samples were refrigerated, and then placed in cryogenic
freezers in barcoded vials until tested. Infants from both studies
were predominantly white, with approximately one-quarter
African-American infants.
Saliva-based binding assays
Saliva samples from adults and infants were tested for potential
age-specific ligand in neonates for P[11] RVs by in vitro binding
assays . Forty-eight saliva from adults, representing different ABO,
secretor and Lewis types described in our previous studies, were
included [5,16]. Seventy-two saliva samples from neonates at day
8 after birth and 79 saliva samples from infants at weeks 4, 13, 26,
and 52 after birth were studied. Saliva samples were boiled for
10 min to inactivate potential antibodies against RVs that could
interfere with the binding assays. The samples then were diluted
1:1,000 and coated on 96-well microtiter plates at 4uC overnight.
After blocking with 5% nonfat cow milk, 100 ml of GST-VP8*
proteins (10 mg/ml) were added and incubated at 37uC for 1 h.
The bound GST-VP8* proteins were detected using a rabbit anti-
GST serum at 1:4000 dilution followed by horseradish peroxidase
(HRP)-conjugated goat anti-rabbit IgG (ICN, Aurora, OH). The
signal intensities were displayed using the TMB kit according to
manufacturer (BD Biosciences, San Diego, CA). In each step, the
plates were incubated for 1 h at 37uC and washed five times with
PBS-Tween 20 using a plate washer. The HBGA types of each
saliva sample were determined by binding assay using monoclonal
antibodies specific to H-1, A, B, Lea, Leb, Lex and Ley antigens as
previously described [5]. The saliva samples were also tested for
binding by lectin Lycopersicon esculentum (LEA) that recognize poly-
LacNAc. The biotin-labeled LEA (Sigma-Aldrich Co., St. Louis,
MO) in dilution of 1:1000 was used, which was detected by HRP-
conjugated-streptavidin (Jackson ImmunoResearch Laboratories
Inc., West Grove, PA) and displayed using the TMB kit
(Kierkegaard and Perry Laboratory, Gaithersburg, MD).
Glycan array screening
The glycan array analysis was performed by the Protein-Glycan
Interaction Core at the Emory University under the Consortium
for Functional Glycomics. A printed glycan array (version 5.0)
consists of 611 glycans in replicates of 6 was used to search for
potential carbohydrate ligands for P[11] RVs (http://www.
functionalglycomics.org/). The recombinant GST-VP8* proteins
were applied to individual glycan arrays at two protein
concentrations (20 and 200 mg/ml respectively), and the bound
GST-VP8* proteins were detected by using a fluorescent-labeled
anti-GST monoclonal antibody. Two sets of relative fluorescent
units (RFU) of each glycan at the two concentration were
calculated and used to rank the specificity of individual glycans
(Table 1) for their interaction with P[11] VP8*.
Oligosaccharide-based binding assay
Synthetic polyacrylamide polymer (PAA) conjugated oligomers
of LacNAc units with variable lengths or fucosyl modifications
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(Table 2) were used to study their specificity as a ligand for P[11]
RVs. Briefly, microtiter plates (Dynex Immulon; Dynatech,
Franklin, MA) were coated with recombinant VP8* proteins
(10 mg/ml) at 4uC overnight. After blocking with 5% nonfat cow
milk, synthetic poly-LacNAc (PAA)-biotin conjugates (Table 2)
obtained from the Consortium for Functional Glycomics or from
GlycoTech Inc. (Gaithersburg, MD) were added at serial dilutions
and incubated at 4uC overnight. The bound oligosaccharides were
then detected using HRP-conjugated-streptavidin (Jackson Im-
munoResearch Laboratories Inc., West Grove, PA) and displayed
Table 1. Data of top 15 glycans ranked highest in binding to P[11] VP8* among 611 glycans tested in the array analysis.
200 mg/ml 20 mg/ml





















































56 8415 53 3755 58
545 Fuca1-2Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-6(Fuca1-2Galb1-4GlcNAcb1-
3Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp24




49 11259 71 1667 26
75 Fuca1-2Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb-Sp0 46 10882 69 1504 23
547 GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-6(GlcNAcb1-3Galb1-
4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp25
46 9669 61 1955 30
aThe highest and lowest points from each set of six replicates were removed to eliminate potential false hits. Binding specificity is shown in mean relative fluorescence
units (RFU) of binding to the four replicates of each glycan printed on the array.
bThe fluorescent signals from each glycan were then normalized to the maximum signal from each assay, and the glycans were ordered according to the average
ranking for the two assays (20 and 200 mg/ml).
Spacer Arm abbreviations: Sp0: -CH2CH2NH2; Sp19: EN or NK; Sp24: KVANKT; Sp25: VANK.
doi:10.1371/journal.pone.0078113.t001
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using the TMB kit (Kierkegaard and Perry Laboratory, Gaithers-
burg, MD).
Binding assay of VP8* to CHO cell mutants
Two mutant cell lines (Lec2 and Lec8) of the Chinese hamster
ovary (CHO) cells were studied for their presence (Lec2) or
absence (Lec8) of poly-LacNAc on their surfaces [17]. The Lec2
and Lec8 mutant cells that were kindly provided by Dr. Pamela
Stanley were grown in monolayer in a-MEM medium supple-
mented with ribonucleosides, deoxyribonucleosides (Gibco), 10%
FBS, 100 unit/mL penicillin, 100 mg/mL streptomycin, and
maintained at 37uC with 5% CO2. The binding of VP8* to the
cells was detected by immunofluorescent method. Briefly, the
monolayer Lec2 and Lec8 cells were grown on poly-L-lysine
treated coverslips to a 90% confluence, and then fixed with 4%
paraformaldehyde. After blocking with 3% BSA, GST-VP8*
fusion protein (100 mg/mL) was added. The binding signal of
VP8* on the cell surface was detected using a rabbit anti-GST
antibody followed by the FITC-conjugated goat anti-rabbit second
antibody.
Virus propagation, inhibition and infectivity assay
Two P[11] RVs, a human strain 116E and a bovine strain B223
[18], were studied for inhibition of replication in cell cultures by
the oligosaccharide of PAA- TriLN and by human milk and saliva
using procedures described previously [19]. Confluent MA-104
cell monolayers were grown on coverslips in 24-well plates. After
rinse twice with serum-free DMEM, 500 ml of serum-free DMEM
was added to each well and the plates were incubated at 37uC for
3 h. For blocking of infection, 300 fluorescent forming units
(FFU)/10 ml of virus were treated with equal volume of serial
dilutions of human milk, LEA positive neonate saliva or PAA-
TriLN at room temperature for 30 min. An adult and a LEA
negative neonate saliva which did not show bindings with P[11]
VP8* were used as controls. Following chilling of all reagents and
the 24-well plates on ice, duplicated wells were inoculated with the
virus-oligosaccharide or virus-saliva/milk mixtures on ice with
continuous rocker platform agitation for 1 h. The inoculum was
then removed and the cells were washed twice with ice-cold
serum-free DMEM. After replacement with 500 ml serum-free
DMEM, the plates were warmed to 37uC and incubated in a 5%
CO2 incubator for 18 to 20 h prior to quantification of infected
cells by immunofluorescence with a rabbit anti-rotavirus antibody
followed by a FITC-labelled goat anti-rabbit secondary antibody.
Hemagglutination assay
Human red blood cells (RBC) of A1, A2, B and O type
(Immucor, Inc., Norcross, GA) were washed twice in PBS before
being tested for hemagglutination with VP8* or authentic RVs. An
equal volume of 50 mL of 1% RBC were added to 50 mL of two-
fold serial dilutions of either the GST-VP8* fusion proteins or
virus on 96-well V-bottom plates. Agglutination was determined
after 2 h of incubation at 4uC.
Statistical analysis
The correlation analysis was conducted using the Pearson
analysis, and the binding signal difference of VP8* to neonate
saliva between 2–13 weeks and 26–52 weeks was assessed by a
two-tailed t test. P values of ,0.05 were considered significant.
Results
VP8* of N155 (P[11] RV) binds saliva exclusively from
neonates/infants but not from adults
To explore potential age-specific receptors for P[11] RVs, we
performed saliva binding assays using recombinant GST-VP8*
fusion protein as described previously [11]. The yields of the fusion
proteins were 5–10 mg/L of bacteria culture and high purity of
the GST-VP8* protein was obtained for the binding assays (data
not shown). Only marginal binding signals (OD,0.35) were
detected among the 48 well-characterized adult saliva samples
(Fig. 1A). However, strong binding signals were observed when the
two sets of neonate/infant saliva samples were tested (60.3%
ODs.0.35, N = 151). High binding signals showed no correlation
with the ABO, secretor and Lewis types (data not shown). The first
set of infant saliva were collected earlier in life (day 8 after birth)
and a higher rate (68.1%) of the samples showed a binding signal
above 0.35 (Fig. 1B). The second set of infant saliva was collected
from a wide age range (weeks 2, 4, 13, 26 and 52 after birth) and
an average 53.2% of positive binding (OD.0.35) was observed.
Moreover, the binding of P[11] VP8* with the saliva showed a
significantly negative correlation with the age of infants (P,0.01).
While most of the positive binding occurred in the early
development stages (weeks 2, 4 and 13), only sporadic binding
was found in saliva collected from infants at weeks 26 and 52
(Fig. 1C).
P[11] VP8* binds poly-LacNAc
To determine the ligand for P[11] VP8* in the infant saliva, we
performed an array assay consisted of 611 oligosaccharide glycans,
and similar binding patterns of the P[11] GST-VP8* fusion
protein at both 20 and 200 mg/ml were observed (Fig. 2A–B). A
group of glycans with a common feature, linear or branched
polymers of the LacNAc disaccharide unit in variable lengths,
ranked the highest (Table 1). Strong binding always occurred to
the poly-LacNAc oligosaccharides without further terminal
modifications. The fucose (a1–2) linked to the terminal Gal of
poly-LacNAc did not affect the binding (Table 1). LacNAc
polymers containing other terminal modifications, such the sialic
acid (Neu5Ac) or GalNAc adding to the terminal galactose
resulted in reduction of the binding. LacNAc is a precursor of
human HBGAs that express abundantly in neonates and young
children. Thus, the glycans of LacNAc polymers could be an age-
specific ligand available to P[11] RVs before the maturation of
HBGAs of neonates.
Results of the oligosaccharide-based binding assay exhibited a
dose-dependent binding to the LacNAc disaccharides, further
confirming that LacNAc is a basic unit recognized by P[11] RVs.
It was noted that the binding signals of P[11] VP8* increased
Table 2. Oligosaccharides used in ELISA for binding to P[11]
VP8*.
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significantly with the numbers of LacNAc repeats, in which the
three repeats (TriLN-PAA) showed the highest signals followed by
the two repeats (DiLN-PAA) and then the single copy (LacNAc-
PAA). No significant difference of P[11] binding to LacNAc
polymers terminated with either a Gal or a GlcNAc residue was
observed. A fucose (a1–2) linked to the terminal Gal did not affect
the P[11] VP8* binding but a fucose (a1–3) linked to the GlcNAc
of a poly-LacNAc totally abolished the binding (Fig. 3).
Poly-LacNAc is also responsible for P[11] binding to
neonatal saliva
To further study the role of LacNAc in P[11] RV host range, we
performed binding assays of the 151neonate/infant saliva samples
with lectin Lycopersicon esculentum (LEA)that recognizes but is not
limited to the poly-LacNAc. Interestingly, none of the 48 adult
saliva samples demonstrated any binding (Fig. 1A). However, a
strong correlation of binding of P[11] with that of the LEA was
observed for the neonate/infant saliva (P,0.01, Fig. 1B and C),
indicating that it is poly-LacNAc in the neonate/infant saliva
responsible for the age-specific binding of P[11]VP8*.
P[11] VP8* binds poly-LacNAc on the surface of CHO cells
Two Chinese hamster ovary (CHO) cell lines, the Lec2 and
Lec8 cells, were chosen for their well-characterized cell surface
glycomics to explore the specific binding for P[11] VP8*. The
Lec2 cells have an inactive cytidine monophosphate (CMP)-sialic
acid Golgi transporter which resulted in a cell surface complex/
hybrid N-glycans mainly consist of poly-LacNAc oligosaccharides
on the cell surfaces, while the Lec8 cells do not express LacNAc
because of a mutant UDP-Gal Golgi transporter gene [17]. Using
immune fluorescence staining methods, the P[11] VP8* displayed
specific binding to the Lec2 cells but not to the Lec8 cells (Fig. 4A),
indicating that P[11] VP8* was selectively attached to the cell-
surface poly-LacNAc of the Lec2 cells.
Figure 1. Binding of recombinant N155 RV VP8* protein to saliva samples collected from adults (A), neonates (B) and infants (C).
The neonate saliva samples were collected at day 8 after birth and the infant saliva samples were collected at weeks 2, 4, 13, 26 and 52 after birth
respectively. The saliva samples also were tested for binding by lectin Lycopersicon esculentum (LEA) that recognizes poly-LacNAc. None of the 48
adult saliva revealed significant binding with either P[11] VP8* or LEA (OD,0.35) but significant binding signals were observed in saliva of neonates
and infants. The binding signals of P[11] VP8* showed a positive correlation with that of LEA among the neonate and infant saliva tested (P,0.01).
The binding signals of P[11] VP8* were negatively correlated with the development stages of the infants (P,0.01), with binding activities in younger
(weeks 2–13) significantly higher than that in older (weeks 26 and 52) infants (P = 0.01).
doi:10.1371/journal.pone.0078113.g001
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Figure 2. Binding of N155 RV VP8* to oligosaccharide glycans by a glycan array assay. The printed array consists of 611 glycans in
replicates of 6. Duplicate sets with the VP8* protein concentrations at 20 (A) and 2 (B) mg/ml were tested. The relative fluorescent units (RFU)
corresponded to strength of binding of individual glycans and the error bar represented the standard deviation of the replicates. The identities of the
glycans used in the array (version 5.0) are available on line (http://www.functionalglycomics.org/). The oligosaccharide glycans ranked highest in
binding to VP8* were listed in the table 1. The schematic structures of representative high ranking glycans are shown (C).
doi:10.1371/journal.pone.0078113.g002
Figure 3. Binding of P[11] VP8* to different forms and modifications of poly-LacNAc by ELISA. LacNAc, a single unit of disaccharide Gal-
GlcNAc; Di-LN, two repeats of the Gal-GlcNAc disaccharide units; Tri-LN, three repeats of the Gal-GlcNAc units; 2F-Di-LN, Di-LN with a a1–2 linked
fucose at a terminal Gal. 39GN-LN, a trisaccharide terminated with the GlcNAc residue. Two oligosaccharides, Lex and Tri-Lex, corresponded to the
disaccharides of LacNAc and the Tri-LN but with a further fucose modification linked (a1–3) to the GlcNAc residues. These oligosaccharides were
conjugated with polyacrylamide (PAA) and were tested with increased concentrations from 2 to 400 mg/ml.
doi:10.1371/journal.pone.0078113.g003
Rotavirus P[11] Binds Poly-LacNAc
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Both P[11] VP8* protein and authentic virus
hemagglutinated human RBCs
Hemagglutination assays of P[11] VP8* as well as two authentic
P[11] RVs (116E and B223) was conducted. A strong agglutina-
tion of human RBCs was obtained for both the P[11] VP8*
protein and the authentic P[11] RVs, irrespective of the ABO
phenotypes, while the VP8* of a P[9] RV, a known type A antigen
binder, agglutinated the type A human RBCs only (Fig. 4B). The
observed unique hemagglutinating property of P[11] RVs was
consistent with the ubiquitous distribution of the poly-LacNAc
relevant antigens (group i and I antigens) found on the surface of
human erythrocyte cells [20].
Inhibition of P[11] RV replication by LacNAc polymers,
human milk and neonate saliva
To examine the biologic relevance of P[11]VP8* binding to
poly-LacNAc, viral replication inhibition assays were performed.
The replications of P[11] RV 116E were significantly reduced
following incubation of the viruses with a LEA positive neonate
saliva (#23) but not with a LEA negative neonate saliva (#45) or
with an adult saliva (OH54). A dose-dependent abrogation with up
to 76.4% reduction of 116E infectivity by the LEA positive
neonate saliva was observed compared to the LEA negative
neonate saliva. Moreover the LEA positive saliva (#23) did not
inhibit the A-antigen binding RV (Arg720) (Fig. 5A, B). The
involvement of poly-LacNAc in RV infection was further
demonstrated by a dose-dependent inhibition of 116E incubated
with LacNAc polymers (TriLN-PAA) but not with the control
oligosaccharide Tri-Lex-PAA (Fig. 5C). Boiled human milk also
blocked 116E replication although reductions were also observed
for the P[9] Arg720 strain (Fig. 5D).
Discussion
In this study we demonstrated that the poly-N-acetyllactosa-
mine (poly-LacNAc) could serve as a potential age-specific ligand
for attachment and infection of RV P[11] in neonates and infants.
A study with similar conclusion was published recently [21].
Evidences of poly-LacNAc as an age-specific ligand in neonates in
our study were obtained by the specific binding of P[11] VP8* to
saliva of neonates and infants but not of adults and by the
significant correlation of binding signals between VP8* and lectin
LEA that recognizes poly-LacNAc. The specificity of RV P[11]
recognizing poly-LacNAc has been further shown by selective
binding of P[11] VP8* to LacNAc polymers by oligosaccharide
Figure 4. Interactions of P[11]VP8* with LacNAc at cellular level. (A) Binding of GST-VP8* to CHO mutants Lec2 (a)–(b) and Lec8 (c)–(d). CHO
mutant Lec2 cells are known to express surface glycans with exclusive end LacNAc oligmeres, while mutant Lec8 cells are absent of LacNAc glycans.
Clear binding signals of P[11] VP8* to the Lec2 but not Lec8 cells are observed. (B) Hemagglutination of P[11] RVs with human red blood cells (RBC).
Cell culture adapted P[11] RV (B223) revealed agglutination with RBCs of all ABO types. The P[9] RVs which are known to bind type A antigens cause
hemagglutination with type A RBCs only.
doi:10.1371/journal.pone.0078113.g004
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glycan array and ELISA, by selective binding of P[11] VP8* to
surfaces of LacNAc-bearing Lac2 cells but not of LacNAc negative
Lac8 cells, and by hemagglutination of both VP8* and authentic
P[11] RVs with human RBCs that are known to express LacNAc
glycans. The biological relevance of poly-LacNAc recognition by
P[11] RVs has been shown by blocking of P[11] RV infection in
cell cultures by poly-LacNAc-PAA oligosaccharide (TriLN-PAA)
and by human milk and infant saliva that bind P[11] VP8*.
The poly-LacNAc structures occur in mammalian glycoproteins
in both N- and O-linked glycans [22]. It is synthesized by repeated
alternating additions of N-acetylglucosamine and galactose,
catalyzed by beta-1,3-N-acetylglucosaminyltransferases (poly-Lac-
NAc synthase) and beta-1,4-galactosyltransferases, respectively,
resulting in multiple repeats of the LacNAc disaccharide unit in
each chain [23,24]. The poly- LacNAc chains represent a
backbone for manifold modifications by variable glycotransferases
such as the fucosyltransferases, sialyltransferases and sulfotrans-
ferases, which further extend to more complex structures [25–27],
and thus were involved in a variety of biological pathways
including immune cell signaling, maintenance of membrane
stability, intracellular sorting of proteins, metastasis and develop-
ment [28].
The roles of poly-LacNAc in metastasis and developmental
regulation are most interesting to our study. The carbohydrates on
the mucosa of neonates mainly may exist in the form of poly-
LacNAc, as demonstrated by the highly occurrence of poly-
LacNAc signals in saliva of neonates. However, the abundance
and size of the poly-LacNAc chains are often reduced during
development [29,30]. Normally, poly-LacNAc is barely detectable
in adult mucosa, except in certain malignant tissues such as
Figure 5. Inhibition of P[11] RV replication in cell cultures by poly-LacNAc conjugates, saliva and human milk. The assay was
performed on P[11] RV 116E growing in MA104 cells. Viruses were incubated with poly-LacNAc conjugates, saliva or human milk at room temperature
for 30 min before being inoculated on MA104 cells. (A) For blocking by saliva, a LEA positive (#23) and a negative (#45) neonate were tested. A
control for the positive neonate saliva (#23) in blocking a type A binder of P[9] RVs was included. (B) Representative immunofluorescence
microscopy images of MA104 cells infected with 116E in an untreated control (top) and LEA positive saliva (#23) treated cells (bottom) are shown. (C)
The PAA conjugated TriLN with three tandem repeats of LacNAc disaccharide units was used at a final concentration of 0.17 and 0.33 mg/ml
respectively. The oligosaccharide Tri-Lex-PAA was used as a control. (D) For blocking by human milk, FPLC fraction F5 of milk 1 which revealed the
highest binding signals to P[11] VP8* was used. The inhibition of P[11] RV infectivity was determined by reduction of fluorescent counts between
PAA-TriLN, saliva and human milk treated and untreated samples.
doi:10.1371/journal.pone.0078113.g005
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colorectal cancer [24,31]. The ‘disappearance’ of poly-LacNAc in
the adult mucosa also could be due to further modification of poly-
LacNAc by variable glycotransferases which may affect its
interaction with P[11] RVs by epitope-blocking or -masking of
the LacNAc residues. Since these glycotransferases are important
in maturation of human HBGAs and other glycans, the age of
neonates and infants for these genes to turn on could be critical for
the different susceptibility of P[11] between neonates/infants and
older children/adults. In this study, saliva samples from neonates
and infants showed high rates of presence of poly-LacNAc and
binding by P[11] VP8* with a negative correlation between P[11]
VP8* binding and the development stages of infants. Binding of
VP8* to infant saliva collected before weeks 13 showed a
significant difference from that of weeks 26 and 52 (P = 0.01),
indicating an age range to turn off the synthesis of poly-LacNAc or
turn on other glycotransferases. Future study to pinpoint these age
ranges is of significance. In addition, some individuals remained
high binding to P[11] VP8* at week 52 after birth, future study to
determine whether the genetic makeup in addition to age variation
also contributing to the poly-LacNAc expression is necessary.
We performed binding assay of P[11] VP8* with variable
amount of monomeric LacNAc and revealed a typical dose-
dependent binding result. We also test poly-LacNAc with either b-
galactose or N-acetylglucosamine as the terminal residues and did
not observe difference in their binding to P[11] VP8*. Poly-
LacNAc with further fucosal modifications either did not affect,
such as an addition of a 1,2-fucose to the terminal galactose, or
completely abolished the binding, such as the addition of a1, 3-
fucose to the N-acetylglucosamine. These results strongly suggest
that the disaccharide LacNAc is the basic unit recognized by P[11]
RVs. However, in a recent study [21], significantly increased
infectivity of P[11] RVs was observed in CHO cells following
transfection with the FUT2 gene, which led to a conclusion that
the a 1,2-fucose played a major role in P[11] binding and
infection. Since there were no binding assay of a 1,2-fucose
modified LacNAc were performed in the study, it is difficult to
determine whether the fucose was actually added to the LacNAc
precursors of the transfected CHO cell surface glycans. Never-
theless, the increased infectivity is not supported by our saliva
binding results nor by the epidemiology of P[11] RVs that mainly
infect neonates and young children. Future study to clarify this
issue may be necessary.
The mechanism of significant higher binding signals of polymers
than monomers of LacNAc remains to be determined. First, the
increased binding activities of P[11] VP8* to poly-LacNAc suggest
increased binding avidities due to multi-repeats in the linear or
multi-antennary chains of poly-LacNAc. Alternatively, increased
binding signals by LacNAc oligomers could be due to increased
freedoms of the terminal LacNAc accessible to VP8* by the
increased lengths of the chains. Our findings on the binding
properties of P[11] VP8* are similar with that of the Ca2+
independent (S-type) lectins such as the galectin family, which
could also bind several LacNAc structures. Likewise, increased
binding was reported accompanied with the adding of the LacNAc
units on the poly-LacNAc chains [32,33]. The crystal forms of
galectin-1 with biantennary glycans revealed the galectin dimers
could be cross-linked by the LacNAc located at the end of the
oligosaccharide antenna; however crystals complexed with internal
LacNAc units have not yet been reported.
Our study also raises questions regarding the epidemiology of
P[11] RVs. For example, although HBGAs related antigens were
also found in animal species, the presence and dynamic change of
the precursor poly-LacNAc on the gastrointestinal epithelia and
their involvement in P[11] infection in cattle remains unknown. A
recent study showed that the P[11] RV could also infect sheep
[34]. It remains inconclusive whether species-specific antigens
and/or age-specific LacNAc are involved in the animal P[11] RV
infection in cattle, sheep or other species. Future study with more
defined animal mucins is necessary. We also tried to determine the
age range for poly-LacNAc after birth of humans, and more follow
up studies on better designed infant populations are needed.
Finally, study of poly-LacNAc in saliva from infants in the south
east Asian countries, particularly in India, is necessary where the
P[11] RVs are more prevalent than other areas of the world.
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